A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer

[1]  C. Lionte,et al.  The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity , 2022, Life.

[2]  M. Ieda,et al.  Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature , 2022, Frontiers in Pharmacology.

[3]  H. Prenen,et al.  Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy , 2021, ESMO open.

[4]  M. Kerneis,et al.  Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. , 2021, JAMA cardiology.

[5]  A. Curtis,et al.  Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis , 2021, Journal for ImmunoTherapy of Cancer.

[6]  L. Galluzzi,et al.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. , 2021, The Journal of clinical investigation.

[7]  A. Bojan,et al.  Assessment and Management of Cardiotoxicity in Hematologic Malignancies , 2021, Disease markers.

[8]  Yong Yi,et al.  Recent updates on Sintilimab in solid tumor immunotherapy , 2020, Biomarker research.

[9]  J. Holfeld,et al.  Cardiotoxic mechanisms of cancer immunotherapy - A systematic review. , 2020, International journal of cardiology.

[10]  A. Lyon,et al.  The Role of Biomarkers in Cardio-Oncology , 2020, Journal of Cardiovascular Translational Research.

[11]  O. Merimsky,et al.  Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis , 2020, Clinical Research in Cardiology.

[12]  Xinchen Sun,et al.  A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. , 2020, Chinese clinical oncology.

[13]  K. Zheng,et al.  Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events , 2020, Thoracic cancer.

[14]  R. Sullivan,et al.  Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. , 2020, European heart journal.

[15]  Huijuan Zhu,et al.  Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction , 2020, Thoracic cancer.

[16]  J. Durand,et al.  Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment , 2020, Journal of the American Heart Association.

[17]  P. Sharma,et al.  Dissecting the mechanisms of immune checkpoint therapy , 2020, Nature Reviews Immunology.

[18]  Jen‐Shi Chen,et al.  Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

[19]  Mengzhao Wang,et al.  Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis , 2019, Thoracic cancer.

[20]  Bo Peng,et al.  Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit , 2019, mAbs.

[21]  Marc P. Bonaca,et al.  Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology , 2019, Circulation.

[22]  Bijie Hu,et al.  Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma. , 2019, Annals of translational medicine.

[23]  L. Cooper,et al.  Management of Myocarditis-Related Cardiomyopathy in Adults. , 2019, Circulation research.

[24]  Y. Shimizu,et al.  Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature , 2019, Internal medicine.

[25]  P. Queirolo,et al.  Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Lipson,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors , 2019, Cardiovascular research.

[27]  Marc P. Bonaca,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.

[28]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[29]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[30]  G. Soulat,et al.  Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. , 2018, European heart journal.

[31]  T. Neilan,et al.  Immune Checkpoint Inhibitor-Associated Myocarditis. , 2018, The oncologist.

[32]  M. Mussap,et al.  Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. , 2018, The oncologist.

[33]  Syed S Mahmood,et al.  Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report , 2018, Gynecologic oncology reports.

[34]  R. Sullivan,et al.  Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action , 2018, The oncologist.

[35]  R. Sullivan,et al.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.

[36]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[37]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  W. Ullah,et al.  New drugs and new toxicities: pembrolizumab-induced myocarditis , 2018, BMJ Case Reports.

[39]  J. Grob,et al.  Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. , 2017, Circulation.

[40]  G. Pontone,et al.  Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function: ITAMY Study. , 2017, Journal of the American College of Cardiology.

[41]  R. Blankstein,et al.  Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. , 2017, Journal of the American College of Cardiology.

[42]  J. Sosman,et al.  Myocarditis with Immune Checkpoint Blockade. , 2017, The New England journal of medicine.

[43]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[44]  Andreas Wicki,et al.  Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study , 2016, Journal of Immunotherapy for Cancer.

[45]  M. Bossard,et al.  Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.

[46]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[47]  Jen‐Shi Chen,et al.  Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword. , 2013, Acta Cardiologica Sinica.

[48]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .

[49]  J. Schulz-Menger,et al.  Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. , 2005, Journal of the American College of Cardiology.

[50]  O Strohm,et al.  Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. , 1998, Circulation.